
Please try another search
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Name | Age | Since | Title |
---|---|---|---|
Ilan Katz | 48 | - | Director |
Jeffrey G. Spragens | 79 | 2020 | Independent Non-Executive Chairman of the Board |
Samuel J. Reich | 46 | 2020 | CEO, CFO & Director |
James J. Martin | 54 | 2020 | Independent Director |
Stephen D. Collins | 68 | 2020 | Independent Director |
William Polvino | - | 2021 | Director |
David Link | - | 2021 | Director |
Eddie Joe Sullivan | - | 2021 | Director |
Christine Hamilton | - | 2021 | Director |
Mervyn Turner | - | 2021 | Director |
Helen K. Ellias | - | 2023 | Director |
David Charles Link | 69 | 2018 | Independent Vice Chairman |
Christine E. Hamilton | 69 | 2014 | Co-Founder & Independent Director |
Michael Haller | - | - | Member of the Clinical Advisory Board & Member of Scientific Advisory Board |
Arturo Casadevall | - | - | Member of Scientific Advisory Board |
Edward D. Hamilton | - | 2021 | Co-Founder & Board Observer |
Mark J. Ratain | 70 | 2022 | Member of Scientific Advisory Board |
Andrew D. Moin | 41 | 2023 | Independent Director |
Jim Robl | - | - | Member of Scientific Advisory Board |
Scott Giberson | 55 | 2022 | Independent Director |
Jeffrey G. Spragens | 83 | 2020 | Independent Director |
Stephen E. Gitelman | - | 2020 | Member of Scientific Advisory Board & Member of Clinical Advisory Board |
Erick J. Lucera | 57 | 2023 | Independent Director |
John Wentworth | - | 2024 | Member of Clinical Advisory Board |
Jay S. Skyler | 78 | 2024 | Independent Director & Member of the Clinical Advisory Board |
Samuel J. Reich | 50 | 2020 | CEO & Executive Chairman |
William J. Polvino | 65 | 2019 | Independent Director |
Chantal Mathieu | - | 2024 | Member of the Clinical Advisory Board |
Jae Hong | - | - | Board Observer |
Eddie Joe Sullivan | 58 | 2014 | Co-Founder, President & Director |
Juan Alvarez | - | 2022 | Member of Scientific Advisory Board |
Helen Katherine Ellias | 46 | 2023 | Independent Director |
Thomas Kay | - | 2024 | Member of the Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review